Medindia

X

Novartis Acquires Rights to GSK's Ofatumumab Drug For Multiple Sclerosis Treatment

by Vishnuprasad on  August 24, 2015 at 6:45 PM Drug News   - G J E 4
Novartis, a Swiss multinational pharmaceutical company, based in Switzerland, has purchased the rights to a multiple sclerosis medication from British pharmaceutical giant GlaxoSmithKline (GSK).
Novartis Acquires Rights to GSK's Ofatumumab Drug For Multiple Sclerosis Treatment
Novartis Acquires Rights to GSK's Ofatumumab Drug For Multiple Sclerosis Treatment
Advertisement

According to sources, the Swiss pharma will handle the worldwide development and commercialization of the drug - Ofatumumab - for use in multiple sclerosis.

Advertisement
The company officials say it is ready to push ahead with all-important phase III clinic trials. Ofatumumab is already widely available from Novartis, but as a cancer drug rather than as a treatment for MS.

Novartis, earlier this year, brought the rights from GlaxoSmithKline to sell Ofatumumab to treat chronic lymphocytic leukaemia.

Sources add that the new deal gives Novartis the right to use Ofatumumab to treat any medical conditions.

For GSK, the deal is part of a strategy to return the business to growth and reverse the trend of the past few years of falling revenues and profits.

The company said the sale of Ofatumumab had 'crystalised' significant value for GSK shareholders.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All